1JS Stock Financial Analysis - Shield Therapeutics plc (DB) Stock

Overview

Shield Therapeutics plc is a specialty pharmaceutical company based in the United Kingdom. Founded in 2008, the company focuses on the development and commercialization of late-stage pharmaceuticals. A key product in its portfolio is Ferric Maltol (marketed as Feraccru/Accrufer), an oral iron treatment designed for patients with iron deficiency anemia, particularly those for whom conventional treatments are unsuitable. Shield Therapeutics operates primarily in the healthcare sector, emphasizing innovation in treatments that aim for better patient compliance and lower side effects compared to traditional therapies. The company has expanded its market across both European and U.S. territories, aiming to fulfill unmet medical needs in the anemia management space.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Shield Therapeutics plc as of 30 June 2025 is 41.49 MM.
The operating income for Shield Therapeutics plc as of 30 June 2025 is -14.61 MM.
The net income for Shield Therapeutics plc as of 30 June 2025 is -21.24 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	41.49	-14.61	-21.24
2025-03-31	36.84	-18.74	-24.21
2024-12-31	32.18	-22.87	-27.18
2024-09-30	26.83	-28.36	-31.67
2024-06-30	21.47	-33.85	-36.17
2024-03-31	17.28	-32.59	-34.73
2023-12-31	13.09	-31.33	-33.29
2023-09-30	9.86	-29.74	-40.28
2023-06-30	6.63	-28.14	-47.28
2023-03-31	6.06	-29.89	-48.53
2022-12-31	5.50	-31.65	-49.79
2022-09-30	4.63	-30.39	-39.36
2022-06-30	3.88	-30.42	-30.18
2022-03-31	2.99	-29.17	-28.64
2021-12-31	1.52	-20.29	-19.68
2021-09-30	1.73	-16.24	-16.36
2021-06-30	1.95	-12.19	-13.04
2021-03-31	6.17	-7.17	-7.83
2020-12-31	10.39	-2.15	-2.63
2020-09-30	9.80	-2.03	-2.06
2020-06-30

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31	-0.03
2024-09-30	-0.04	-0.04
2024-06-30	-0.05	-0.05
2024-03-31	-0.05	-0.05
2023-12-31	-0.05
2023-09-30	-0.07	-0.07
2023-06-30	-0.10	-0.10
2023-03-31	-0.14	-0.14
2022-12-31	-0.21
2022-09-30	-0.17	-0.17
2022-06-30	-0.14	-0.14
2022-03-31	-0.13	-0.13
2021-12-31	-0.10
2021-09-30	-0.09	-0.09
2021-06-30	-0.09	-0.09
2021-03-31	-0.06	-0.06
2020-12-31	-0.02
2020-09-30	-0.02	-0.02
2020-06-30	-0.01	-0.01

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Shield Therapeutics plc as of 30 June 2025 is 5.05 MM.
The cash from investing activities for Shield Therapeutics plc as of 30 June 2025 is -2.49 MM.
The cash from financing activities for Shield Therapeutics plc as of 30 June 2025 is -0.61 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	5.05	-2.49	-0.61
2025-03-31	-0.86	-2.32	0.41
2024-12-31	-6.77	-2.15	1.43
2024-09-30	-13.78	-2.04	9.53
2024-06-30	-20.80	-1.92	17.63
2024-03-31	-28.96	-2.18	33.64
2023-12-31	-37.13	-2.43	49.66
2023-09-30	-32.64	-2.37	44.22
2023-06-30	-28.15	-2.30	38.78
2023-03-31	-25.37	-2.28	23.66
2022-12-31	-22.59	-2.25	8.53
2022-09-30	-24.16	-2.86	4.21
2022-06-30	-26.76	-3.68	-0.11
2022-03-31	-25.89	-3.29	18.16
2021-12-31	-18.26	-2.05	27.71
2021-09-30	-14.87	-1.25	27.70
2021-06-30	-11.48	-0.44	27.68
2021-03-31	-6.44	-0.23	13.82
2020-12-31	-1.40	-0.02	-0.05
2020-09-30	-0.74	0.06	-0.10
2020-06-30

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31	0.00	-1.03
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31	0.00	-0.07
2022-12-31
2022-09-30
2022-06-30
2022-03-31	0.00	-0.09
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30

Management Effectiveness

The roa for Shield Therapeutics plc as of 30 June 2025 is -0.58.
The roe for Shield Therapeutics plc as of 30 June 2025 is -39.26.
The roic for Shield Therapeutics plc as of 30 June 2025 is -1.08.
The croic for Shield Therapeutics plc as of 30 June 2025 is -0.30.
The ocroic for Shield Therapeutics plc as of 30 June 2025 is -0.27.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.58	-39.26	-1.08	-0.30	-0.27
2025-03-31	0.00	0.00
2024-12-31	-0.74	-1.81	-1.76	-0.27	-1.01
2024-09-30	-0.74	-2.11	-1.76	-0.27	-1.01
2024-06-30	-0.80	-1.28	-0.94	0.30	-1.05
2024-03-31
2023-12-31	-1.82	-7.42	-1.23	0.32	-0.99
2023-09-30	-1.36	-1.50	-1.49	0.36	-0.84
2023-06-30	-1.13	-1.50	-1.49	0.36	-0.84
2023-03-31		0.00	0.00	0.01
2022-12-31	-0.54	-0.78	-5.92	-2.72	-3.29
2022-09-30	-0.54	-0.58	-5.83	-2.67	-3.24
2022-06-30	0.00	-0.47	-0.73	-0.62	-0.53
2022-03-31	0.00	0.00	0.00
2021-12-31	-0.40	-0.43	-0.47	0.22	-0.22
2021-09-30	-0.50	-0.53	-0.39	0.31	-0.22
2021-06-30	-0.34	-0.37	-0.26	0.32	-0.22
2021-03-31	-0.20	-0.22	-0.15	0.15	-0.13
2020-12-31	-0.07	-0.08	-0.09	-0.04	-0.05
2020-09-30	-0.06	-0.06	-0.07	-0.02	-0.02
2020-06-30	-0.04	-0.04	-0.04	-0.00	-0.00

Gross Margins

The gross margin for Shield Therapeutics plc as of 30 June 2025 is 0.46.
The net margin for Shield Therapeutics plc as of 30 June 2025 is -0.84.
The operating margin for Shield Therapeutics plc as of 30 June 2025 is -0.71.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	0.46	-0.84	-0.71
2025-03-31
2024-12-31	0.36	-1.68	-1.58
2024-09-30	0.36	-1.68	-1.58
2024-06-30	0.31	-2.54	-2.39
2024-03-31	0.45	-6.61	-3.94
2023-12-31	0.36	-3.97	-2.93
2023-09-30	0.45	-6.61	-3.94
2023-06-30	0.45	-6.61	-3.94
2023-03-31		0.00	-4.71
2022-12-31	0.53	-8.53	-6.60
2022-09-30	0.53	-8.53	-6.60
2022-06-30		-7.77	-7.83
2022-03-31		0.00	-9.59
2021-12-31	0.61	-12.73	-13.13
2021-09-30	0.61	-9.33	-9.27
2021-06-30	0.61	-6.69	-6.25
2021-03-31	0.83	-1.27	-1.16
2020-12-31	0.87	-0.25	-0.21
2020-09-30	0.88	-0.21	-0.21
2020-06-30	0.87	-0.16	-0.21